As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week ...

Now, time is of the essence for it to pass. In addition to helping Americans access the medicines they need, savings from biosimilars are critical to cutting costs in government health care ...

Celltrion Inc.’s biosimilar versions of Amgen Inc.’s blockbuster bone-strengthening drugs Prolia and Xgeva are blocked in the US until June 1 as part of a settlement agreement, according to a filing ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch. Celltrion’s Stelara biosimilar ustekinumab ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term comparable efficacy and safety up to week 52. Patients with psoriasis who switched ...

Known as AVT05, the Alvotech medication is a proposed biosimilar to Simponi, prescribed to treat various inflammatory conditions. The FDA is set to review the Biologics License Applications (BLAs) for ...

The reality is that people can only focus on one thing at a time. If given the choice between you and a flashy PowerPoint slide, the slides will win every time. That’s bad news if you want your ...

In 2025, the three largest pharmacy benefit managers are largely rejecting biosimilars from their formularies, with the exception of their own private-label medicines, Drug Channels reported Jan. 22.

Surveying the next 12 months, J&J expects to chart roughly 3% sales growth to $91.3 billion in 2025 by “overcoming headwinds associated with U.S. biosimilar entries for Stelara,” as well as ...